Oct 26, 2014 – Alectos today announced publication of preclinical studies showing that pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in the TAPP mouse model of Alzheimer’s disease. For details, see: Yuzwa, S.A. et al. Mol Neurodegener 9:42 (2014).
Oct 6, 2014 – Alectos today announced its support for NSERC funding for the group of Prof. M.J. Boulanger at the University of Victoria, Department of Biochemistry & Microbiology, in a project titled “Cloning and expression of human glucocerebrosidase”. Parkinson’s disease (PD) is a worldwide health problem that is characterized by the buildup of abnormal [...]
Alectos Therapeutics Announces Achievement of Preclinical Milestone in Merck Alzheimer’s Collaboration
Vancouver, British Columbia (November 16, 2012) – Alectos Therapeutics Inc. today announced the achievement of a preclinical milestone in its research collaboration with Merck, known as MSD outside the U.S. and Canada, to identify and develop compounds that modulate O-linked N-acetylglucosaminidase (OGA), an enzyme that is believed to be involved in the development of Alzheimer’s [...]
Collaboration Targets a Potential Non-Amyloid Approach to Treating Alzheimer’s Disease Vancouver, Canada (August 11, 2010) – Alectos Therapeutics Inc. today announced a research collaboration with Merck, headquartered in Whitehouse Station, N.J., to identify and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) an enzyme that is believed to be involved in the development of Alzheimer’s disease [...]